BR9707325A - Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma - Google Patents

Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma

Info

Publication number: BR9707325A
Authority: BR; Brazil
Prior art keywords: pharmaceutical composition; treatment; mediated disease; affected patient; effective amount
Prior art date: 1996-02-09

Application number

BR9707325A

Other languages

English (en)

Inventor

David S Collins

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-09

Filing date

1997-02-10

Publication date

1999-04-13

1997-02-07 Priority claimed from US08/798,414 external-priority patent/US6096728A/en

1997-02-10 Application filed by Amgen Inc filed Critical Amgen Inc

1999-04-13 Publication of BR9707325A publication Critical patent/BR9707325A/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Inorganic Chemistry (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Biochemistry (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Nutrition Science (AREA)

BR9707325A 1996-02-09 1997-02-10 Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma BR9707325A (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US1141996P	1996-02-09	1996-02-09
US3278996P	1996-12-06	1996-12-06
US3624197P	1997-01-23	1997-01-23
US08/798,414 US6096728A (en)	1996-02-09	1997-02-07	Composition and method for treating inflammatory diseases
PCT/US1997/002131 WO1997028828A1 (en)	1996-02-09	1997-02-10	Composition comprising interleukin-1 inhibitor and controlled release polymer

Publications (1)

Publication Number	Publication Date
BR9707325A true BR9707325A (pt)	1999-04-13

Family

ID=27486083

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9707325A BR9707325A (pt)	1996-02-09	1997-02-10	Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma

Country Status (19)

Country	Link
EP (1)	EP0904112B1 (pt)
JP (2)	JP4344404B2 (pt)
KR (1)	KR20040010739A (pt)
CN (1)	CN1215340A (pt)
AT (1)	ATE448797T1 (pt)
AU (1)	AU724960C (pt)
BR (1)	BR9707325A (pt)
CA (2)	CA2539273C (pt)
CZ (1)	CZ299025B6 (pt)
DE (1)	DE69739656D1 (pt)
EA (2)	EA001792B1 (pt)
ES (1)	ES2334726T3 (pt)
HU (1)	HU230160B1 (pt)
IL (1)	IL125552A0 (pt)
MX (1)	MX9806191A (pt)
NO (1)	NO983543L (pt)
NZ (2)	NZ503548A (pt)
SK (1)	SK288144B6 (pt)
WO (1)	WO1997028828A1 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0949931B1 (en)	1996-12-06	2008-08-27	Amgen Inc.,	Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US7488590B2 (en)	1998-10-23	2009-02-10	Amgen Inc.	Modified peptides as therapeutic agents
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
ATE348163T1 (de)	1998-10-23	2007-01-15	Amgen Inc	Thrombopoietin substitute
AT406054B (de) *	1998-11-04	2000-02-25	Andreas Bernkop-Schnuerch	Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
ATE311868T1 (de) *	1999-06-21	2005-12-15	Santen Pharmaceutical Co Ltd	Arzneimittel für die rheumatoide arthritis
CA2378880C (en) *	1999-07-21	2010-02-23	Omeros Medical Systems, Inc.	Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP2003533187A (ja) *	2000-05-03	2003-11-11	アムジエン・インコーポレーテツド	治療薬としてのＦｃドメインを含む修飾ペプチド
US7324635B2 (en)	2000-05-04	2008-01-29	Telemaze Llc	Branch calling and caller ID based call routing telephone features
WO2001087328A2 (en) *	2000-05-12	2001-11-22	Immunex Corporation	Interleukin-1 inhibitors in the treatment of diseases
PT1324776E (pt)	2000-10-12	2009-12-23	Genentech Inc	Formulações de proteína concentradas de viscosidade reduzida
US8703126B2 (en)	2000-10-12	2014-04-22	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
US7087224B2 (en)	2000-10-31	2006-08-08	Amgen Inc.	Method of treating anemia by administering IL-1ra
PH12012502439A1 (en)	2001-06-26	2013-06-17	Amgen Inc	Antibodies to opgl
US6818613B2 (en)	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
WO2003061626A1 (en) *	2002-01-18	2003-07-31	Control Delivery Systems, Inc.	Polymeric gel system for the controlled delivery of codrugs
MXPA04011470A (es)	2002-05-21	2005-02-14	Amgen Inc	Compuestos heterociclicos sustituidos y metodos de uso.
EP2277543B1 (en)	2002-09-06	2015-12-16	Amgen, Inc	Therapeutic anti-IL-1R1 monoclonal antibody
US7344716B2 (en)	2003-05-13	2008-03-18	Depuy Spine, Inc.	Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en)	2003-08-13	2009-06-30	Depuy Spine, Inc.	Transdiscal administration of cycline compounds
US8273347B2 (en)	2003-05-13	2012-09-25	Depuy Spine, Inc.	Autologous treatment of degenerated disc with cells
US7429378B2 (en)	2003-05-13	2008-09-30	Depuy Spine, Inc.	Transdiscal administration of high affinity anti-MMP inhibitors
US8361467B2 (en)	2003-07-30	2013-01-29	Depuy Spine, Inc.	Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en)	2003-11-26	2014-11-25	DePuy Synthes Products, LLC	Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
CA2557910C (en) *	2004-04-02	2012-05-29	Amgen Inc.	Methods of reducing aggregation of il-1ra
WO2006036834A2 (en)	2004-09-24	2006-04-06	Amgen Inc.	MODIFIED Fc MOLECULES
SI2664334T1 (sl) *	2004-12-30	2015-06-30	Genzyme Corporation	Reĺ˝imi za intraartikularno viskosuplemantacijo
EP2664340B1 (en) *	2005-06-24	2020-02-12	Duke University	A direct drug delivery system based on thermally responsive biopolymers
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
PE20070684A1 (es)	2005-11-14	2007-08-06	Amgen Inc	MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US7833527B2 (en)	2006-10-02	2010-11-16	Amgen Inc.	Methods of treating psoriasis using IL-17 Receptor A antibodies
GB0708376D0 (en)	2007-05-01	2007-06-06	Alligator Bioscience Ab	Novel polypeptides and uses thereof
EP2217258B1 (en)	2007-11-14	2014-03-26	General Regeneratives Limited	Use of interleukin-1 receptor antagonist as a myeloprotective agent
US8986696B2 (en)	2007-12-21	2015-03-24	Depuy Mitek, Inc.	Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
PL2259774T3 (pl)	2008-02-27	2013-04-30	Biomet Biologics Llc	Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
KR200451958Y1 (ko) *	2008-10-09	2011-01-21	(주)에이치시티	모바일기기용 카드형 안테나장치
CN102414221A (zh)	2009-03-06	2012-04-11	健泰科生物技术公司	抗体配制剂
US20110052561A1 (en) *	2009-08-27	2011-03-03	Biomet Biologics,LLC	Osteolysis treatment
TW201117824A (en)	2009-10-12	2011-06-01	Amgen Inc	Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh)	2009-10-26	2012-08-01	上海交通大学	白细胞介素-1受体拮抗剂的用途及其药物组合物
DE202009017772U1 (de)	2009-12-10	2011-04-21	Orthogen Ag	Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
TW201527322A (zh) *	2011-02-08	2015-07-16	Abbvie Inc	骨關節炎及疼痛之治療
WO2012108828A1 (en)	2011-02-11	2012-08-16	Swedish Orphan Biovitrum Ab (Publ)	Citrate free pharmaceutical compositions comprising anakinra
US20140234330A1 (en)	2011-07-22	2014-08-21	Amgen Inc.	Il-17 receptor a is required for il-17c biology
CN103781473A (zh)	2011-09-02	2014-05-07	诺维信生物制药丹麦公司	包含用于持续药物释放的透明质酸的口服配制品
US10143725B2 (en)	2013-03-15	2018-12-04	Biomet Biologics, Llc	Treatment of pain using protein solutions
US9758806B2 (en)	2013-03-15	2017-09-12	Biomet Biologics, Llc	Acellular compositions for treating inflammatory disorders
US9895418B2 (en)	2013-03-15	2018-02-20	Biomet Biologics, Llc	Treatment of peripheral vascular disease using protein solutions
US9878011B2 (en)	2013-03-15	2018-01-30	Biomet Biologics, Llc	Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en)	2013-03-15	2014-09-18	Biomet Biologics, Llc	Treatment of collagen defects using protein solutions
EP3054982B1 (en) *	2013-10-08	2019-05-01	Ascendis Pharma A/S	Hydrogel-linked il-1ra prodrug
US20160000936A1 (en)	2014-06-10	2016-01-07	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
CZ309295B6 (cs) *	2015-03-09	2022-08-10	Contipro A.S.	Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití
US10041044B2 (en)	2016-07-29	2018-08-07	Trustees Of Boston University	Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
JP7216006B2 (ja)	2017-03-22	2023-01-31	ジェネンテック，インコーポレイテッド	ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
US11819536B2 (en)	2018-06-22	2023-11-21	The Trustees Of Columbia University In The City Of New York	Sustained release compositions and methods for treatment of temporomandibular joint degeneration
WO2020035482A1 (en)	2018-08-13	2020-02-20	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP3886809A4 (en) *	2018-11-28	2022-03-30	Genascence Corporation	METHODS AND COMPOSITIONS FOR THE TREATMENT OF OSTEOARTHRITIS
CN114206366A (zh)	2019-08-08	2022-03-18	艾维登斯医疗公司	基于微球的可注射塞来昔布制剂
EP4526469A1 (en)	2022-05-16	2025-03-26	Institut National de la Santé et de la Recherche Médicale	Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
KR900700134A (ko)	1988-04-15	1990-08-11	원본미기재	Il-2 수용체-특이적 키메릭 항체
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
ATE289350T1 (de)	1989-04-21	2005-03-15	Amgen Inc	Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
IL95031A (en)	1989-07-18	2007-03-08	Amgen Inc	Method for the production of a human recombinant tumor necrosis factor inhibitor
CA2065346C (en)	1989-09-05	2005-03-29	Craig A. Smith	Tumor necrosis factor-.alpha. and-.beta. receptors
AU649245B2 (en) *	1990-04-02	1994-05-19	Amgen, Inc.	Methods for treating interleukin-1 mediated diseases
US6552170B1 (en)	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
US6458360B1 (en)	1990-04-25	2002-10-01	The Johns Hopkins University	Soluble complement regulatory molecules
AU7683391A (en)	1990-04-27	1991-11-27	Upjohn Company, The	Modified interleukin-1 inhibitors
DE69233069T2 (de)	1991-03-15	2003-11-27	Amgen Inc., Thousand Oaks	Pegylation von polypeptiden
NO940913L (no) *	1993-03-26	1994-09-27	Bristol Myers Squibb Co	Preparater for kontrollert frigivelse av biologisk aktiv TGF-
JPH06321803A (ja) *	1993-05-17	1994-11-22	Kirin Brewery Co Ltd	水溶性ペプチドホルモンの徐放性製剤
US5385887A (en) *	1993-09-10	1995-01-31	Genetics Institute, Inc.	Formulations for delivery of osteogenic proteins
WO1995010298A1 (en) *	1993-10-12	1995-04-20	Mary Lake Polan	Method of contraception
US5446090A (en)	1993-11-12	1995-08-29	Shearwater Polymers, Inc.	Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU698393B2 (en) *	1994-06-24	1998-10-29	Immunex Corporation	Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
IT1269989B (it)	1994-09-21	1997-04-16	Dompe Spa	Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria

1997
- 1997-02-10 CA CA2539273A patent/CA2539273C/en not_active Expired - Lifetime
- 1997-02-10 DE DE69739656T patent/DE69739656D1/de not_active Expired - Lifetime
- 1997-02-10 KR KR10-2003-7016565A patent/KR20040010739A/ko not_active Ceased
- 1997-02-10 IL IL12555297A patent/IL125552A0/xx unknown
- 1997-02-10 AU AU21213/97A patent/AU724960C/en not_active Expired
- 1997-02-10 CN CN97193632A patent/CN1215340A/zh active Pending
- 1997-02-10 CZ CZ0237398A patent/CZ299025B6/cs not_active IP Right Cessation
- 1997-02-10 BR BR9707325A patent/BR9707325A/pt not_active Application Discontinuation
- 1997-02-10 WO PCT/US1997/002131 patent/WO1997028828A1/en not_active Ceased
- 1997-02-10 NZ NZ503548A patent/NZ503548A/en unknown
- 1997-02-10 HU HU9902612A patent/HU230160B1/hu unknown
- 1997-02-10 JP JP52874197A patent/JP4344404B2/ja not_active Expired - Lifetime
- 1997-02-10 EA EA199800694A patent/EA001792B1/ru not_active IP Right Cessation
- 1997-02-10 NZ NZ331163A patent/NZ331163A/xx unknown
- 1997-02-10 CA CA002244664A patent/CA2244664C/en not_active Expired - Lifetime
- 1997-02-10 EA EA200000825A patent/EA200000825A1/ru unknown
- 1997-02-10 SK SK1036-98A patent/SK288144B6/sk not_active IP Right Cessation
- 1997-02-10 EP EP97906551A patent/EP0904112B1/en not_active Expired - Lifetime
- 1997-02-10 AT AT97906551T patent/ATE448797T1/de not_active IP Right Cessation
- 1997-02-10 ES ES97906551T patent/ES2334726T3/es not_active Expired - Lifetime
1998
- 1998-07-31 NO NO983543A patent/NO983543L/no not_active Application Discontinuation
- 1998-07-31 MX MX9806191A patent/MX9806191A/es active IP Right Grant
2007
- 2007-05-22 JP JP2007136048A patent/JP2007211027A/ja active Pending

Also Published As

Publication number	Publication date
NZ331163A (en)	2000-07-28
NO983543D0 (no)	1998-07-31
JP4344404B2 (ja)	2009-10-14
HU230160B1 (hu)	2015-09-28
KR20040010739A (ko)	2004-01-31
CA2244664C (en)	2008-06-03
CA2244664A1 (en)	1997-08-14
AU724960B2 (en)	2000-10-05
AU2121397A (en)	1997-08-28
NZ503548A (en)	2001-09-28
JP2007211027A (ja)	2007-08-23
SK288144B6 (sk)	2013-12-02
JP2001500472A (ja)	2001-01-16
DE69739656D1 (de)	2009-12-31
NO983543L (no)	1998-10-08
EA200000825A1 (ru)	2001-02-26
CA2539273A1 (en)	1997-08-14
EA199800694A1 (ru)	1999-02-25
EP0904112B1 (en)	2009-11-18
MX9806191A (es)	1998-10-31
CZ299025B6 (cs)	2008-04-02
EA001792B1 (ru)	2001-08-27
SK103698A3 (en)	2001-01-18
CZ237398A3 (cs)	1999-09-15
WO1997028828A1 (en)	1997-08-14
CA2539273C (en)	2014-02-04
ES2334726T3 (es)	2010-03-15
EP0904112A1 (en)	1999-03-31
HUP9902612A3 (en)	2001-11-28
HUP9902612A2 (hu)	1999-11-29
AU724960C (en)	2002-08-15
IL125552A0 (en)	1999-03-12
ATE448797T1 (de)	2009-12-15
CN1215340A (zh)	1999-04-28

Publication	Publication Date	Title
BR9707325A (pt)	1999-04-13	Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
BRPI9908182B8 (pt)	2018-08-14	composições de proteína de matriz para cura de feridas
ES2059965T3 (es)	1994-11-16	Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
BR9507506A (pt)	1997-09-02	Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
BR9812753A (pt)	2000-08-29	Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
BR0015974A (pt)	2002-07-23	Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
PT1079806E (pt)	2006-06-30	Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
BR9006924A (pt)	1991-12-10	Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
UA41989C2 (uk)	2001-10-15	Фармацевтична композиція у вигляді гелю для лікування захворювань шкіри та спосіб лікування інфікованої шкіри
BR9406979A (pt)	1996-03-05	Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
BR0115531A (pt)	2004-02-03	Tratamento de mucosites
DK0607128T4 (da)	2007-05-07	Lægemiddel samt fremstilling deraf og anvendelse deraf ved bekæmpelsen af smerter og/eller betændelser hos dyr og mennesker
BR9715022A (pt)	2001-09-18	Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
DE69025943D1 (de)	1996-04-18	Verwendung von Spiperone-derivate zur Immunosuppression
BR9809117A (pt)	2000-08-01	Composição de gel retardado de liberação prolongada, processo de produzir a mesma, formulação farmacêutica,e , processos de tratamento de uma indicação , de uma doença, e de uma inflamação com uma composição de liberação prolongada
ID27502A (id)	2001-04-12	Turunan-turunan 3-(amino-atau aminoalkil) piridinon dan penggunannya untuk pengobatan penyakit-penyakit yang berkaitan dengan hiv
ES2173111T3 (es)	2002-10-16	Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
NO20004282D0 (no)	2000-08-25	Matriksproteinpreparater for sÕrheling
BR9502471A (pt)	1996-05-21	Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
IT1282736B1 (it)	1998-03-31	Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
BR0308957A (pt)	2005-02-01	Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
PT900563E (pt)	2004-06-30	Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
PT92995A (pt)	1990-07-31	Metodo para o tratamento da disfuncao leucocita com gm-csf
BR9610211A (pt)	1999-12-21	Composições farmacêuticas baseadas em gel tipo gliceril poli(meta)acrilato
ATE185274T1 (de)	1999-10-15	Therapeutisches mittel gegen drohenden abortus

Legal Events

Date	Code	Title	Description
2003-09-09	FA	Application withdrawn